Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular TargetsCorrado Pelaia, Giorgio Walter Canonica, Enrico Heffler et al.|Frontiers in Pharmacology|2022Cited by 157
Molecular Targets for Biological Therapies of Severe AsthmaCorrado Pelaia, Girolamo Pelaia, Claudia Crimi et al.|Frontiers in Immunology|2020Cited by 132
Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter StudySanti Nolasco, Nunzio Crimi, Alida Benfante et al.|The Journal of Allergy and Clinical Immunology In Practice|2021Cited by 83
Tezepelumab: A Potential New Biological Therapy for Severe Refractory AsthmaCorrado Pelaia, Alessandro Vatrella, Giulia Pelaia et al.|International Journal of Molecular Sciences|2021Cited by 74
Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug doseCorrado Pelaia, Girolamo Pelaia, Maria Teresa Busceti et al.|Pulmonary Pharmacology & Therapeutics|2019Cited by 62